… The introduction of levodopa in the late 1960s represented a landmark in the therapy of
Parkinson's disease (PD). However, motor complications of chronic levodopa therapy have …

… the disease process itself and influences therapeutic options, which are often limited because
of additional morbidity with necessary concomitant drug therapy. … Parkinson's disease. The …

… Preclinical validation of Bach1 inhibition for the development of Parkinson's disease
therapy Society for Neuroscience 2016 Session 787 - Parkinson's Neuroprotection II, 787.21/I9. …

… show the importance of DNA methylation in regulating motor functions in PD and can thus
be proved pharmacologically important for the therapeutic strategy in the Parkinson disease. …

… therapeutic approaches. Herein we present an overview of current gene therapy clinical trials
for Parkinson’s disease. … The first two therapies discussed in this article focus on increasing …

… therapies in AD and Parkinson's disease (PD). These new technologies include disease-…
In addition, nanotechnology-based drug discovery has revolutionized therapeutic prospects …

… is typically treated with oral dopamine replacement therapies; … therapy aimed at restoring
local and continuous dopamine production in patients with advanced Parkinson's disease. …

… gene therapy approaches. This review presents an overview of the four gene therapies in …
strategies that might improve the clinical prospects of gene therapy for PD. In so doing, we …

Parkinson's disease (PD) is a common, progressive neurodegenerative disorder characterized
by substantia nigra dopamine cell death and a varied clinical picture that affects older …

Parkinson’s disease (PD) is a common neurodegenerative disorder primarily characterized
by the death of dopaminergic neurons that project from the substantia nigra pars compacta. …